1 / 7

Everotas 5mg tablet - Everolimus | Myapplepharma

Everotas 5mg contains an active compound known as Everolimus which interferes with the development of cancer cell and the process is slowed down, this tablet is not a curable medication, which helps to slow their spreading into the body.

RobbieRoyce
Download Presentation

Everotas 5mg tablet - Everolimus | Myapplepharma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Apple Pharmaceuticals We will not dispense any prescription medication without a valid prescription from a licensed physician

  2. Everolimus Everotas 5mg Tablets

  3. DESCRIPTION • PRESCRIBED FOR • The drug Everotas 5mg is mainly used for the treatment of following disease • • kidney carcinoma • • Breast carcinoma • • Brain carcinoma • Everotas 5mg is also used to treat in various advanced stage cancer in stomach, intestines or pancreas. Everotas 5mg is belongs to class of anti-cancer drugs Everotas 5mg contains of an active compound known as Everolimus which is interfere with development of cancer cell and process is slows down. Everotas 5mg tablets is not a curable medication, which is helps to slow their spreading into the body.

  4. CLINICAL PHARMACOLOGY OF EVEROTAS Everolimus is an prohibitor of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis. Everotas also prohibits the expression of hypoxia-inducible factor, causing to a reduces in the expression of vascular endothelial growth factor. The results of everolimus prevention of mTOR is a reduction in cell multiplication, angiogenesis, and glucose uptake.

  5. DOSAGE • DRUG-DRUG INTERACTION Everotas 5mg tablets should be given with or without food. Dosage regimen of Everotas; In breast cancer, renal cell cancer, pancreatic cancer, Neuro endocrine cancer: The prescribed dosage is 10mg should be taken as a single dose. In Brain or intracranial cancer: The prescribed dosage of Everotas as a single dose. is 4.5mg/m2 given orally In pediatric: The pediatric dosage of Everotas as a single dose in brain or intracranial tumor is 4.5mg/m2 should be given orally. • Interaction of Everotas 5mg with strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus. Concomitant use of Everotas 5mg with strong CYP3A4 inducers, will increasing the disclosure of Everolimus.

  6. MISSED DOSE • LACTATION • Breast feeding should not be suggested If the patients missed dose, patients must consult with medical practitioner and follow the instructions given by them. Or missed dose should be avoid and follow the regular dosing schedule. • STORAGE • Everotas 5mg tablet store at 25° Protect the medicine away from moisture, heat and light.

  7. CONTACT US CALL • +91-9987711567 MAIL • applepharamaceutical@gmail.com ADDRESS Apartment No.304 A Wing, Shiva Shakthi chs ltd, JP Road, Near Apna Bazar,Andheri(West),Mumbai - 400058.Maharashtra.

More Related